A prospective survey study on premenstrual syndrome in young and middle aged women with an emphasis on its management

Shruti Brahmbhatt, B. M. Sattigeri, Heena Shah, Ashok Kumar, Devang Parikh


Premenstrual syndrome (PMS) is defined as the recurrence of psychological and physical symptoms in the luteal phase, which remit in the follicular phase of the menstrual cycle. Symptoms of which fall in three domains: emotional, physical and behavioural e.g. irritability, anger, headache, fatigue, food cravings etc. The survey study of was conducted among 50 young & 50 middle aged women of S.B.K.S Medical Institute and Research Centre to find the prevalence of premenstrual syndrome with an emphasis on its management. Responses to a feedback questionnaire covering various aspects related PMS were obtained from 50 participants belonging to each group. The participants belonged to different range of literacy. It was found that 42% faced PMS regularly, while 58% occasionally. Of the 100 participants 68% suffered with backache, 64% leg cramps, 62% fatigue, breast tenderness and anger whereas 58% suffered with anxiety and generalized body ache. Of all the sufferers only 34% had received the treatment for PMS. Irrespective of the age PMS is common problem faced by women. With our study we observed that literacy has not mattered in the management of this health problem. Since there are reports stating that the severity of PMS can hamper the daily routine and even lead to suicidal tendency, it is essential that awareness programs need to be conducted to address the importance of managing the issue by pharmacological and non-pharmacological methods.


Premenstrual syndrome, Luteal phase, Follicular phase

Full Text:



Myint TH, Edessa OG, Sawhsarkapaw. Premenstrual syndrome among female university students in Thailand. AU JT 2006;9:158-62.

Rasheed P, Al-sowielem LS. Prevalence and predictors of premenstrual syndrome among college-aged women in Saudi Arabia. Annals of Saudi Medicine 2003;6:381-7.

Pearlstein T, Steiner M. Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 2008;33:291-301.

Joshi JV, Pandey SN, Galvankar P, Gogate JA. Prevalence of premenstrual symptoms: preliminary analysis and brief review of management strategies. Journal of mid-life health 2010;1:30-4.

Lolas J. Premenstrual Syndrome: A neglected public health problem (Spanish). Rev Med Chil 1993;121:560-6.

Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.

Endicott J, Amsterdam J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Womens Health Gend Based Med 1999;8:663-79.

Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000;13:287-304.

Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 2003;28(Suppl 3):55-99.

Parry BL. Psychobiology of premenstrual dysphoric disorder. Semin Reprod Endocrinol 1997;15:55-68.

Eriksson O, Backstrom T, Stridsberg M, et al. Differential response to estrogen challenge test in women with and without premenstrual dysphoria. Psychoneuroendocrinology 2006;31:415-27.

Epperson CN, Haga K, Mason GF, et al. Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002;59:851-8.

Smith MJ, Adams LF, Schmidt PJ, et al. Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol Psychiatry 2003;54:757-62.

Kurshan N, Epperson CN. Oral contraceptives and mood in women with and without premenstrual dysphoria: a theoretical model. Arch Womens Ment Health 2006;9:1-14.

Schultz-Zehden B, Boschitsch E. User experience with an oral contraceptive containing ethinylestradiol 30mug and drospirenone 3mg (YASMIN®) in clinical practice. Treat Endocrinol 2006;5:251-6.

Rapkin AJ. New treatment approaches for premenstrual disorders. Am J Manag Care 2005;11(Suppl):S480-91.

Wyatt KM, Dimmock PW, Ismail KM, et al. The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 2004;111:585-93.

Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001;323:776-80.

Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv 1983;38:643-6.

Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998;179:444-52.

Kashanian M, Mazinani R, Jalalmanesh S. Pyridoxine (vitamin B6) therapy for premenstrual syndrome. Int J Gynaecol Obstet 2007;96:43-4.

Bryant M, Cassidy A, Hill C, et al. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005;93:731-9.